Ohnoshi T, Ueoka H, Kawahara S, Numata T, Nishii K, Yonei T, Mima Y, Horiguchi T, Kiura K, Moritaka T
Department of Internal Medicine II, Okayama University Medical School.
Rinsho Hoshasen. 1990 Jul;35(7):779-87.
In order to assess the development of treatments and the curability of small cell lung cancer, we analysed a total of 239 patients entered in our protocol study since 1976. Median survival time was 68 weeks for 127 patients with limited disease and 48 weeks for 112 with extensive disease. Three-year survival rate was 18% for those with limited disease, whereas it was only 5% for extensive disease. The median survival time and long-term disease-free survival rate has been improved with an introduction of aggressive chemotherapy including new drugs such as etoposide and cisplatin. Chest irradiation in addition to intensive chemotherapy played a substantial, but not significant, role for prolonging patient survival in those with limited disease. Nevertheless, the pace of therapeutic advances has been slowed and appears to reach a plateau. In this paper, the authors try to find some obstacles in the treatment of the disease, and to indicate some strategies to gain a progress.
为了评估小细胞肺癌治疗方法的发展及可治愈性，我们分析了自1976年起纳入我们方案研究的总共239例患者。127例局限性疾病患者的中位生存时间为68周，112例广泛性疾病患者的中位生存时间为48周。局限性疾病患者的三年生存率为18%，而广泛性疾病患者仅为5%。随着包括依托泊苷和顺铂等新药在内的积极化疗的引入，中位生存时间和长期无病生存率得到了改善。除强化化疗外，胸部放疗在延长局限性疾病患者的生存时间方面发挥了重要但不显著的作用。然而，治疗进展的步伐已经放缓，似乎达到了一个平台期。在本文中，作者试图找出该疾病治疗中的一些障碍，并指出一些取得进展的策略。
